Form 8-K - Current report:
SEC Accession No. 0001641172-25-026448
Filing Date
2025-09-04
Accepted
2025-09-03 17:44:18
Documents
14
Period of Report
2025-09-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 49311
2 EX-99.1 ex99-1.htm EX-99.1 16807
  Complete submission text file 0001641172-25-026448.txt   283047

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lixt-20250903.xsd EX-101.SCH 3784
4 XBRL DEFINITION FILE lixt-20250903_def.xml EX-101.DEF 26650
5 XBRL LABEL FILE lixt-20250903_lab.xml EX-101.LAB 36768
6 XBRL PRESENTATION FILE lixt-20250903_pre.xml EX-101.PRE 25274
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5794
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251291279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)